Published in J Clin Oncol on August 01, 1997
Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer | NCT02963090
Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry (2004) 10.58
Immune surveillance of tumors. J Clin Invest (2007) 5.04
Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin Proc (2010) 3.25
Antibodies and neuronal autoimmune disorders of the CNS. J Neurol (2009) 2.40
Orchiectomy for suspected microscopic tumor in patients with anti-Ma2-associated encephalitis. Neurology (2006) 2.25
The RNA-binding protein Elavl1/HuR is essential for placental branching morphogenesis and embryonic development. Mol Cell Biol (2009) 1.78
EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays. Tumour Biol (2012) 1.52
Immune response in lung cancer mouse model mimics human anti-Hu reactivity. J Neuroimmunol (2009) 1.47
Paraneoplastic syndromes: when to suspect, how to confirm, and how to manage. J Neurol Neurosurg Psychiatry (2004) 1.34
Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neuro Oncol (2004) 1.29
Small-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy. Mol Cancer (2011) 1.10
Paraneoplastic syndromes in patients with primary malignancies of the head and neck. Four cases and a review of the literature. Eur Arch Otorhinolaryngol (2005) 1.07
Paraneoplastic antigen Ma2 autoantibodies as specific blood biomarkers for detection of early recurrence of small intestine neuroendocrine tumors. PLoS One (2010) 1.04
Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes? J Thorac Oncol (2016) 1.03
Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies: A beneficial antitumor immune response going awry. Oncoimmunology (2013) 0.99
Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique. Clin Exp Immunol (2006) 0.98
Are onconeural antibodies a clinical phenomenology in paraneoplastic limbic encephalitis? Mediators Inflamm (2013) 0.96
Anti-Hu antibody titre and brain metastases before and after treatment for small cell lung cancer. J Neurol Neurosurg Psychiatry (1999) 0.95
Small cell lung cancer: will recent progress lead to improved outcomes? Clin Cancer Res (2015) 0.94
Autoimmune encephalitis: A potentially reversible cause of status epilepticus, epilepsy, and cognitive decline. Ann Indian Acad Neurol (2013) 0.94
Low level anti-Hu reactivity: A risk marker for small cell lung cancer? Cancer Detect Prev (2008) 0.88
ZIC antibodies in paraneoplastic cerebellar degeneration and small cell lung cancer. J Neuroimmunol (2008) 0.86
Isoaspartylation appears to trigger small cell lung cancer-associated autoimmunity against neuronal protein ELAVL4. J Neuroimmunol (2016) 0.85
Tolerance to the neuron-specific paraneoplastic HuD antigen. PLoS One (2009) 0.85
Paraneoplastic limbic encephalitis, an uncommon presentation of a common cancer: Case report and discussion. Am J Case Rep (2013) 0.84
Paraneoplastic neurological syndromes associated with ovarian tumors. J Cancer Res Clin Oncol (2014) 0.84
Paraneoplastic sensorimotor neuropathy associated with regression of small cell lung carcinoma. BMJ Case Rep (2010) 0.83
Locally advanced lung cancer: an optimal setting for vaccines and other immunotherapies. Cancer J (2013) 0.82
Antinuclear antibodies define a subgroup of paraneoplastic neuropathies: clinical and immunological data. J Neurol Neurosurg Psychiatry (2005) 0.80
Autoimmune and antitumor consequences of antibodies against antigens shared by normal and malignant tissues. J Clin Immunol (2000) 0.80
T cells targeting a neuronal paraneoplastic antigen mediate tumor rejection and trigger CNS autoimmunity with humoral activation. Eur J Immunol (2014) 0.79
Small cell lung cancer (SCLC): no treatment advances in recent years. Transl Lung Cancer Res (2016) 0.79
Update on paraneoplastic neurologic disorders. Oncologist (2010) 0.77
Antibodies as Mediators of Brain Pathology. Trends Immunol (2015) 0.77
The great masquerader of malignancy: chronic intestinal pseudo-obstruction. Biomark Res (2014) 0.76
Novel Humoral Prognostic Markers in Small-Cell Lung Carcinoma: A Prospective Study. PLoS One (2015) 0.76
Human epidermal growth factor receptor 2 overexpression in breast cancer of patients with anti-Yo--associated paraneoplastic cerebellar degeneration. Neuro Oncol (2012) 0.76
Cell-mediated immune responses in paraneoplastic neurological syndromes. Clin Dev Immunol (2013) 0.76
The Roles of Radiotherapy and Immunotherapy for the Treatment of Lymphoma. Mol Cell Pharmacol (2013) 0.75
Antibodies to aquaporin-4 in non-small cell lung cancer: a study on 50 patients. Neurol Sci (2010) 0.75
Prognostic effect of early treatment of paraneoplastic limbic encephalitis in a patient with small-cell lung cancer. Curr Oncol (2012) 0.75
Two Paraneoplastic Autoimmune Syndromes: Limbic Encephalitis and Palmar Fasciitis in a Patient with Small Cell Lung Cancer. Rare Tumors (2015) 0.75
Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC. J Thorac Oncol (2016) 0.75
Bilateral Vocal Cord Paralysis and Cervicolumbar Radiculopathy as the Presenting Paraneoplastic Manifestations of Small Cell Lung Cancer: A Case Report and Literature Review. Case Rep Otolaryngol (2016) 0.75
Small Cell Lung Cancer Accompanied by Tonsillar Metastasis and Anti-Hu Antibody-Associated Paraneoplastic Neuropathy: A Rare Case Report With Long-Term Survival. Medicine (Baltimore) (2015) 0.75
Paraneoplastic limbic encephalitis in a patient with extensive disease small-cell lung cancer. Mol Clin Oncol (2017) 0.75
Paraneoplastic syndromes (PNS) associated with Merkel cell carcinoma (MCC): A case series of 8 patients highlighting different clinical manifestations. J Am Acad Dermatol (2016) 0.75
Paraneoplastic neurological syndrome in a patient with gastric cancer. Gastric Cancer (2010) 0.75
Synchronous Adie's syndrome and type 1 antineuronal nuclear antibody (anti-Hu)-related paraneoplastic neurological syndromes as predictors of complete response in limited-stage small-cell lung cancer: A case report. Mol Clin Oncol (2017) 0.75
Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain (2000) 7.95
Neurological complications of acquired immune deficiency syndrome: analysis of 50 patients. Ann Neurol (1983) 5.98
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer (2001) 5.36
Association between coffee drinking and K-ras mutations in exocrine pancreatic cancer. PANKRAS II Study Group. J Epidemiol Community Health (1999) 4.43
Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer (1982) 4.40
Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumours. Lancet (1992) 3.85
A serologic marker of paraneoplastic limbic and brain-stem encephalitis in patients with testicular cancer. N Engl J Med (1999) 3.58
HuD, a paraneoplastic encephalomyelitis antigen, contains RNA-binding domains and is homologous to Elav and Sex-lethal. Cell (1991) 3.33
Anti-Hu--associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore) (1992) 3.21
Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res (1999) 3.15
Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology (1992) 3.11
Distribution of brain metastases. Arch Neurol (1988) 3.11
Epidural spinal cord compression from metastatic tumor: diagnosis and treatment. Ann Neurol (1978) 3.08
Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM). Ann Oncol (2010) 3.00
Nova, the paraneoplastic Ri antigen, is homologous to an RNA-binding protein and is specifically expressed in the developing motor system. Neuron (1993) 2.81
Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch (2001) 2.73
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer (2005) 2.71
Limbic encephalitis and small cell lung cancer. Clinical and immunological features. Brain (1997) 2.64
Radiation-induced dementia in patients cured of brain metastases. Neurology (1989) 2.59
Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer--a quantitative western blot analysis. Ann Neurol (1990) 2.58
Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration. N Engl J Med (1990) 2.54
Cerebrovascular complications in patients with cancer. Medicine (Baltimore) (1985) 2.39
Vectorial targeting of apical and basolateral plasma membrane proteins in a human adenocarcinoma epithelial cell line. Proc Natl Acad Sci U S A (1989) 2.36
Ma1, a novel neuron- and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders. Brain (1999) 2.35
Infiltration of the leptomeninges by systemic cancer. A clinical and pathologic study. Arch Neurol (1974) 2.33
A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol (1999) 2.32
Effect of brain irradiation on demyelinating lesions. Neurology (1993) 2.21
Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst (1991) 2.19
Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology (2000) 2.17
Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Ann Neurol (2001) 2.15
Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology (1979) 2.13
Incomplete overlapping of biological, clinical, and environmental information in molecular epidemiological studies: a variety of causes and a cascade of consequences. J Epidemiol Community Health (2002) 2.13
Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J (2010) 2.08
Cloning of a brain protein identified by autoantibodies from a patient with paraneoplastic cerebellar degeneration. Proc Natl Acad Sci U S A (1987) 2.05
Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol (2007) 1.96
Spinal-fluid pH and neurologic symptoms in systemic acidosis. N Engl J Med (1967) 1.93
Intracranial metastases from systemic cancer. Adv Neurol (1978) 1.92
The expression of the Hu (paraneoplastic encephalomyelitis/sensory neuronopathy) antigen in human normal and tumor tissues. Am J Pathol (1992) 1.91
Neuronal antinuclear antibody in sensory neuronopathy from lung cancer. Neurology (1985) 1.86
Improving strategies for detecting genetic patterns of disease susceptibility in association studies. Stat Med (2008) 1.86
Motor neuron syndromes in cancer patients. Ann Neurol (1997) 1.82
Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer. Int J Cancer (1994) 1.82
MRI changes in intracranial hypotension. Neurology (1993) 1.80
Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology (2010) 1.80
Sensory neuronopathy and small cell lung cancer. Antineuronal antibody that also reacts with the tumor. Am J Med (1986) 1.79
Subacute encephalitis in acquired immune deficiency syndrome: a postmortem study. Am J Clin Pathol (1984) 1.79
MUC6 apomucin shows a distinct normal tissue distribution that correlates with Lewis antigen expression in the human stomach. Gastroenterology (1995) 1.75
Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol (1999) 1.74
Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma. Eur Respir J (2011) 1.74
Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain (1997) 1.73
Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Ann Oncol (2011) 1.73
Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol (2004) 1.71
Brachial plexus lesions in patients with cancer: 100 cases. Neurology (1981) 1.70
Altered HOX and WNT7A expression in human lung cancer. Proc Natl Acad Sci U S A (2000) 1.69
Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer. Gastroenterology (1998) 1.69
Radiation therapy for brain metastases. Ann Neurol (1980) 1.68
Quality of life during chemotherapy in non-small cell lung cancer patients. Acta Oncol (1989) 1.68
Epidural spinal cord compression from metastatic tumor: results with a new treatment protocol. Ann Neurol (1980) 1.68
Autoantibodies in paraneoplastic syndromes associated with small-cell lung cancer. Neurology (1988) 1.66
Cerebral metabolic and circulatory responses to induced convulsions in animals. Arch Neurol (1968) 1.66
Phenotypic heterogeneity of melanoma. Relation to the differentiation program of melanoma cells. J Exp Med (1987) 1.65
Autoantibody synthesis in the central nervous system of patients with paraneoplastic syndromes. Neurology (1990) 1.65
Paraneoplastic cerebellar degeneration: clinical-immunological correlations. Ann Neurol (1988) 1.63
Basic molecular genetics for epidemiologists. J Epidemiol Community Health (2003) 1.62
Metastasis to the base of the skull: clinical findings in 43 patients. Neurology (1981) 1.61
Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation. Cancer Res (1986) 1.60
Cancer diagnosis disclosure in a Spanish hospital. Ann Oncol (1992) 1.60
Perforation of the gastrointestinal tract in patients receiving steroids for neurologic disease. Neurology (1988) 1.59
Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol (1999) 1.58
Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol (2006) 1.58
Subacute sensory neuropathy: a remote effect of carcinoma. Ann Neurol (1977) 1.58
Steroid myopathy in cancer patients. Neurology (1997) 1.57
Epidemiology of inclusion body myositis in the Netherlands: a nationwide study. Neurology (2000) 1.57
Ataxia in epidural spinal cord compression. Neurology (1992) 1.55
Neurologic complications of carcinoid. Neurology (1986) 1.54
Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann Oncol (2005) 1.51
Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutations. Eur Respir J (2009) 1.51
Diagnostic certainty and potential for misclassification in exocrine pancreatic cancer. PANKRAS I Project Investigations. J Clin Epidemiol (1994) 1.50
Endometrioid carcinoma of the ovary: a retrospective study. Br J Obstet Gynaecol (1988) 1.49
Class 1 (unique) tumor antigens of human melanoma. Identification of a 90,000 dalton cell surface glycoprotein by autologous antibody. J Exp Med (1984) 1.48
Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal autoantibodies. Neurology (1992) 1.47
Autoimmune response of patients with paraneoplastic cerebellar degeneration to a Purkinje cell cytoplasmic protein antigen. Ann Neurol (1985) 1.46
Subacute motor neuronopathy: a remote effect of lymphoma. Ann Neurol (1979) 1.42
Clinical characterisation of Becker muscular dystrophy patients predicts favourable outcome in exon-skipping therapy. J Neurol Neurosurg Psychiatry (2013) 1.42
Paraneoplastic cerebellar degeneration. III. Cerebellar degeneration, cancer, and the Lambert-Eaton myasthenic syndrome. Neurology (1992) 1.41
Influence of "diagnostic delay" upon cancer survival: an analysis of five tumour sites. J Epidemiol Community Health (1991) 1.41
Cloning of a leucine-zipper protein recognized by the sera of patients with antibody-associated paraneoplastic cerebellar degeneration. Proc Natl Acad Sci U S A (1991) 1.41
[Experience with 150 subcutaneous venous reservoirs for venous access and infusion for the treatment of adult patients with oncologic and hematologic disorders and acquired immunodeficiency syndrome]. Med Clin (Barc) (1992) 1.40
Differential expression of the human mucin genes MUC1 to MUC5 in relation to growth and differentiation of different mucus-secreting HT-29 cell subpopulations. J Cell Sci (1993) 1.40
The role of postoperative radiotherapy after resection of single brain metastases. Neurosurgery (1989) 1.40
Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies. J Neurol Neurosurg Psychiatry (1996) 1.39
Three families with polyneuropathy associated with monoclonal gammopathy. Arch Neurol (2000) 1.39